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 Summary 
    Recent regulatory warnings about 
adverse behavioural effects of 
antidepressants in susceptible 
individuals have raised the proﬁ  le of 
these issues with clinicians, patients, 
and the public. We review available 
clinical trial data on paroxetine and 
sertraline and pharmacovigilance 
studies of paroxetine and ﬂ  uoxetine, 
and outline a series of medico-legal 
cases involving antidepressants and 
violence.
    Both clinical trial and 
pharmacovigilance data point to 
possible links between these drugs 
and violent behaviours. The legal 
cases outlined returned a variety of 
verdicts that may in part have stemmed 
from different judicial processes. 
Many jurisdictions appear not to 
have considered the possibility that a 
prescription drug may induce violence. 
    The association of antidepressant 
treatment with aggression and violence 
reported here calls for more clinical 
trial and epidemiological data to be 
made available and for good clinical 
descriptions of the adverse outcomes 
of treatment. Legal systems are likely 
to continue to be faced with cases 
of violence associated with the use 
of psychotropic drugs, and it may 
fall to the courts to demand access 
to currently unavailable data. The 
problem is international and calls for 
an international response.
  Introduction
    In 1989, Joseph Wesbecker shot dead 
eight people and injured 12 others 
before killing himself at his place of 
work in Kentucky. Wesbecker had been 
taking the selective serotonin reuptake 
inhibitor (SSRI) antidepressant 
ﬂ  uoxetine for four weeks before these 
homicides, and this led to a legal action 
against the makers of ﬂ  uoxetine, Eli 
Lilly [1]. The case was tried and settled 
in 1994, and as part of the settlement 
a number of pharmaceutical company 
documents about drug-induced 
activation were released into the 
public domain. Subsequent legal cases, 
some of which are outlined below, 
have further raised the possibility of a 
link between antidepressant use and 
violence. 
    The issue of treatment-related 
activation has since then been 
considered primarily in terms of 
possible increases in the risk of 
suicide among a subgroup of patients 
who react adversely to treatment. 
This possibility has led regulatory 
authorities to warn doctors about the 
risk of suicide in the early stages of 
treatment, at times of changing dosage, 
and during the withdrawal phase of 
treatment. Some regulators, such as the 
Canadian regulators, have also referred 
to risks of treatment-induced activation 
leading to both self-harm and harm 
to others [2]. The United States labels 
for all antidepressants as of August 
2004 note that “anxiety, agitation, 
panic attacks, insomnia, irritability, 
hostility, aggressiveness, impulsivity, 
akathisia (psychomotor restlessness), 
hypomania, and mania have been 
reported in adult and pediatric patients 
being treated with antidepressants for 
major depressive disorder as well as 
for other indications, both psychiatric 
and nonpsychiatric” [3]. Despite these 
developments, few data are available on 
the links between antidepressant usage 
and violence. We here offer new data, 
review the implications of these data, 
and summarise a series of medico-legal 
cases.
    This paper focuses on paroxetine 
primarily because we have access 
to more illustrative medico-legal 
case material for this drug than for 
other antidepressants. Secondly, the 
manufacturer, GlaxoSmithKline, 
submitted data on the rates of 
occurrence of “hostile” episodes on 
paroxetine for the recent review of 
antidepressant drugs undertaken 
by the British regulator [4,5]. It 
is not clear that the review team 
obtained comparable data for other 
antidepressants. 
  Sources  of  Data
      Data presented to regulatory 
agencies.   The data submitted by 
GlaxoSmithKline on paroxetine for 
review by the Committee on Safety of 
Medicines Expert Working Group are 
described as a complete set of data 
from all placebo-controlled trials of this 
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drug [5]. The use of this dataset thus 
involves no selection by the authors, 
and any selection bias there might 
have been on the part of the company 
seems unlikely to have increased 
the size of the problem. Data from 
placebo-controlled trials of sertraline 
in children are also presented, as 
these also offer a complete dataset, so 
minimising any selection bias. 
      Data from United Kingdom 
Drug Safety Research Unit (DSRU) 
prescription-event monitoring studies 
on paroxetine and ﬂ  uoxetine [6,7].
        Legal cases in which the authors 
have given evidence.   We have selected 
these only to illustrate the range of 
medico-legal problems such cases can 
pose. In the majority of other cases in 
which the authors were consulted, they 
considered that the drug in question 
was not linked to the behaviour for 
which the defendant was charged. 
      E-mails from 1,374 patients in 
response to a BBC programme on 
paroxetine broadcast in 2002.   One of 
us (AH) had the opportunity to analyse 
a complete set of these responses.
    Summary of Evidence Found
      Data from regulatory agencies.   In 
paroxetine clinical trials, aggression 
and violence were commonly coded 
under the rubric of hostility. This 
coding term includes homicide, 
homicidal acts, and homicidal ideation 
as well as aggressive events and 
“conduct disorders”, but no homicides 
were reported from these trials. The 
material posted on the company Web 
site (http:⁄⁄www.gsk.com) suggests that 
these hostile behaviours in children 
primarily involved aggression rather 
than frank violence. When hostile 
events occurring in both adult and 
paediatric trials are summed, both on 
therapy and during the 30-day drug-
free phase after taper had ﬁ  nished, 60 
(0.65%) of 9,219 patients overall had 
hostile events. Table 1 shows the results 
[5]. 
    In these trials, hostile events are 
found to excess in both adults and 
children on paroxetine compared 
with placebo, and are found across 
indications, and both on therapy and 
during withdrawal. The rates were 
highest in children with obsessive-
compulsive disorder (OCD), where 
the odds ratio of a hostile event was 17 
times greater (95% conﬁ  dence interval 
[CI], 2.22–130.0). 
    In their submissions to 
the Committee on Safety of 
Medicines Expert Working Group, 
GlaxoSmithKline also reported 
that 11,491 patients entered trials 
comparing paroxetine with other 
antidepressants [5]. In this patient 
cohort, 44 hostile events occurred on 
paroxetine or other drugs, a rate of 
0.38%. In the subset of trials comparing 
paroxetine with another SSRI, there 
were 16 hostile events in 2,418 patients 
(0.66%). These SSRI comparator trials 
may be confounded by indication; 
the SSRI comparator trials might, 
for instance, have included a higher 
proportion of patients with OCD.
    Finally, in healthy volunteer 
studies, hostile events occurred in 
three of 271 (1.1%) volunteers taking 
paroxetine, compared with zero in 
138 taking placebo [5]. Although not 
statistically signiﬁ  cant, this ﬁ  nding 
is striking because hostile events are 
unusual in healthy volunteer trials, 
and this ﬁ  gure was higher than the 
rate reported in clinical populations 
above. GlaxoSmithKline ascribed 
these episodes to the fact that the 
volunteers were conﬁ  ned, although 
this applied to both paroxetine and 
placebo volunteers. One other healthy 
volunteer study has reported aggressive 
behaviour in one volunteer taking 
sertraline [8]. 
    In data from sertraline paediatric 
trials submitted by Pﬁ  zer, aggression 
was the joint commonest cause 
for discontinuation from the two 
sertraline placebo-controlled trials in 
depressed children [9]. In these trials, 
eight of 189 patients randomised to 
sertraline discontinued for aggression, 
agitation, or hyperkinesis (a coding 
term for akathisia), compared with 
no dropouts for these reasons in 
184 patients on placebo (95% CI, 
1.72–inﬁ  nity). When discontinuations 
for any manifestation of treatment-
induced activation (suicidal 
ideation or attempts, aggression, 
agitation, hyperkinesis, or aggravated 
depression) were considered, there 
were 15 discontinuations on sertraline 
compared with two on placebo, a 
relative risk of 7.3 (95% CI, 1.70–31.5; 
  p   = 0.0015). The report of these 
studies does not include an analysis 
of these data [9]. In the only other 
placebo-controlled sertraline paediatric 
trial, undertaken in children and 
adolescents with OCD, there were 
ten dropouts out of 92 patients on 
sertraline, ﬁ  ve of whom discontinued 
for behavioural activation, two for 
agitation, one for aggression, one for 
nervousness, and one for emotional 
lability. In comparison, there was one 
discontinuation for hyperkinesis out of 
a total of two dropouts from 95 patients 
on placebo [10]. 
    Finally, in paediatric trials of 
venlafaxine (Wyeth), two percent 
of children dropped out because of 
hostility, more than double the rate of 
dropout on placebo [11].
    By 2003, 121 cases of aggression on 
paroxetine had been reported to the 
Medicines and Healthcare Products 
Regulatory Agency (MHRA), and by 
January 2006 that number had risen 
to 211 [12]. It should be noted that 
such reporting systems estimate that 
physicians report between one and ten 
percent of adverse effects on treatment 
[13]. 
      DSRU data.   Evidence from two 
DSRU prescription-event monitoring 
studies of paroxetine and ﬂ  uoxetine 
[6,7] is shown in Table 2, summarising 
details of aggressive events and assaults 
in patients prescribed ﬂ  uoxetine and 
paroxetine in primary care after the 
launches of these two drugs. These data 
are consistent with the clinical trial data 
reported above. The greatest frequency 
  Table 1.   Hostility Events in Adult and Paediatric Placebo-Controlled Trials on Therapy 
and in Withdrawal Phase    
Condition Paroxetine Events/Patients Placebo Events/Patients Odds Ratio 
(95% CI)
Overall  60/9219 (0.65%) 20/6,455 (0.31%) 2.10 (1.27–3.48)
Depression 20/3,799 (0.53%) 8/2,402 (0.33%) 1.58 (0.70–3.58)
OCD 19/737 (2.58%) 5/470 (1.06%) 2.43 (0.91–6.45)
Anxiety 16/3,823 (0.42%) 7/3,404 (0.21%) 2.03 (0.84–4.84)
PMDD 5/760 (0.66%) 0/379
 From  [5].
    PMDD, premenstrual dysphoric disorder.
  DOI:  10.1371/journal.pmed.0030372.t001 
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of events was during the ﬁ  rst month of 
treatment (unpublished data).
      The medico-legal cases.   Nine 
illustrative cases in which we have 
between us acted as expert witnesses 
are summarised in Table 3. In eight 
of them the person who was taking 
an antidepressant was the defendant; 
in one (DS; see Annex), the patient 
killed three members of his family and 
then himself, and his son-in-law sued 
SmithKline Beecham. We have chosen 
the cases to demonstrate the diversity of 
the issues they raise. They are described 
in the Annex.
      E-mails from patients to a BBC 
television programme.   After a 
programme on paroxetine in 2002, 
the producers of the BBC television 
programme   Panorama   received 1,374 
e-mails from viewers, mostly patients. 
One of us (AH) was able to analyse 
the full set of these responses. Many 
linked emotional storms and thoughts 
and acts of violence or self-harm to 
paroxetine, both to starting drug 
treatment and to dosage change. 
These were not simple anecdotal 
reports, in that the analysis clearly 
pointed to a linkage with dosage. 
Second, they were self-reports of 
violence from patients with no 
apparent background of violent 
behaviour [14]. Third, the analysis was 
consistent with an analysis of reports 
of thoughts and acts of violence or 
self-harm on paroxetine that doctors 
had sent to the MHRA about other 
patients between 1991 and 2002 [15]. 
In both patient and medical reports, 
severe mood changes were commonly 
associated with changes of drug dosage 
during the ﬁ  rst week of treatment, 
with later dosage increase, or with 
dosage decrease or drug withdrawal. 
The accounts reported in both the 
medical and the patient series had 
much in common, including time 
frame and a linkage to dosage [15]. 
  Discussion
      Mechanisms of antidepressant-induced 
violence.   A link between antidepressant 
use and violence needs a plausible 
clinical mechanism through which 
such effects might be realised. There 
are comparable data on increased rates 
of suicidal events on active treatment 
compared to placebo [16,17]. In the 
case of suicide, several explanations 
have been offered for the linkage. 
It is argued that alleviating the 
motor retardation of depression, the 
condition being treated, might enable 
suicides to happen, but this cannot 
explain the appearance of suicidality in 
healthy volunteers. Mechanisms linking 
antidepressant treatment, rather than 
the condition, to adverse behavioural 
outcomes include akathisia, emotional 
disinhibition, emotional blunting, 
and manic or psychotic reactions to 
treatment. There is good evidence that 
antidepressant treatment can induce 
problems such as these and a prima 
facie case that akathisia, emotional 
blunting, and manic or psychotic 
reactions might lead to violence.
      Akathisia.   Some of the best 
descriptions of akathisia come from 
the medical literature on the use of 
reserpine as an anti-hypertensive in the 
mid-1950s [18]:
    “Increased tenseness, restlessness, 
insomnia and a feeling of being very 
uncomfortable”.
    “On the ﬁ  rst day of treatment he 
reacted with marked anxiety and 
weepiness, on the second day felt 
so terrible with such marked panic 
at night that the medication was 
cancelled”.
    “The ﬁ  rst few doses frequently 
made them anxious and apprehensive. 
They reported increased feelings of 
strangeness, verbalised by statements 
such as ‘I don’t feel myself’ or ‘I’m 
afraid of some of the unusual impulses 
I have’”. 
    Events such as these in clinical trials 
of antidepressants have commonly 
been coded under headings such 
as agitation, emotional lability, and 
hyperkinesis (overactivity), and only 
rarely to akathisia. In clinical practice 
the term has sometimes been restricted 
to states of demonstrable motor 
restlessness, but by deﬁ  nition it cannot 
be a simple motor disorder or it would 
be classiﬁ  ed as a dyskinesia [19]. 
There is good evidence that akathisia 
can exacerbate psychopathology in 
general [20] and consensus that it can 
be linked to both suicide and violence 
[21,22]. A link between akathisia and 
violence, including homicide, following 
antipsychotic use has previously been 
reported [23–25].
    Substantial evidence from SSRI 
clinical trials shows that these drugs 
can trigger agitation. Approximately 
ﬁ  ve percent of patients on SSRIs in 
randomised trials drop out for agitation 
against 0.5% on placebo. The current 
data sheets for SSRI antidepressants 
specify that the drugs can cause 
akathisia and agitation, and warn 
about developing suicidality in the 
early phase of treatment, on treatment 
discontinuation, and in the wake of a 
dosage increase during the course of 
treatment. In the US, these warnings 
explicitly apply to not only depressed 
patients but also people being treated 
for anxiety, smoking cessation, or 
premenstrual dysphoric disorder. In 
Canada, warnings specify an increased 
risk of violence in addition to suicide. 
      Emotional blunting.   Another 
mechanism that may contribute to 
hostile events is treatment-induced 
emotional blunting. Several reports 
published since 1990 have linked 
SSRI intake with the production of 
emotional blunting, detachment, or 
an amotivational syndrome, described 
in one report as the equivalent to a 
“chemical lobotomy” [26–29]. It is 
quite common in clinical practice to 
ﬁ  nd people who say they simply are 
not bothered any more. Things that 
would previously have worried them no 
longer do so. However, clinical trials of 
antidepressants have so far not assessed 
this phenomenon and its frequency is 
not reliably known.
      Mania and psychosis.   Another 
mechanism that may link SSRIs to 
violence are the manic or psychotic 
states reported to be induced by drug 
treatment. These drug-induced states 
  Table 2.   DSRU: Prescription-Event Monitoring Studies of Paroxetine and Fluoxetine   
Event Paroxetine 
(  n  = 13,741) First 
Six Months of 
Treatment
Paroxetine 
(  n  = 13,741) 
Overall
Fluoxetine 
(  n  = 12,692) First 
Six Months of 
Treatment
Fluoxetine 
(  n  = 12,692) 
Overall
Aggression  18 (0.13%) 36 (0.26%) 20 (0.16%) 48 (0.38%)
Assault  7 (0.05%) 19 (0.14%) 10 (0.08%) 12 (0.10%)
Murder 1100
Total 26 (0.19%) 56 (0.41%) 30 (0.24%) 60 (0.47%)
  Paroxetine  ﬁ  gures from [6], Appendix 2; ﬂ  uoxetine ﬁ  gures from [7], Appendix 2.
  DOI:  10.1371/journal.pmed.0030372.t002 
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often resolve once the medication is 
removed. However, the full dimensions 
of treatment-induced psychotic or 
manic reactions have yet to be mapped; 
some may continue for a long period 
after treatment has stopped [30]. It 
has recently been estimated that these 
drug-induced manic or psychotic states 
may account for up to eight percent 
of admissions to psychiatric facilities 
[31–35].
    The development of a psychotic 
episode or of command hallucinations 
has traditionally been linked to both 
violence and suicide. The labels for 
most SSRIs now concede a causal 
relationship to psychosis and to 
hallucinations. 
    A proportion of these cases with 
superﬁ  cially manic or psychotic 
reactions and unrecognised confusion 
may be delirious states reﬂ  ecting 
organic brain disturbances rather than a 
functional psychosis or mania. Delirium 
is an absolute defence against murder, 
while psychosis and mania may not be. 
      Somnambulism.   Another mechanism 
that may be relevant to violence and 
murder is sleepwalking. Somnambulism 
can provide an absolute defence 
against murder, in that the defendant 
in such a case does not have the 
capacity to form intent. Several reports 
have been published of an association 
of paroxetine with sleepwalking in 
people not previously known to have 
sleepwalked [36,37]; somnambulism 
has also been reported for other 
SSRIs [37]. Among the drugs linked 
to sleepwalking in reports to the UK 
MHRA up to January 2006, paroxetine 
came second with 12 reports, and 
zopiclone ﬁ  rst with 13 reports, with 
antidepressants occupying eight of the 
top 17 slots. 
    Paroxetine has also been reported to 
the MHRA more often than any other 
drug for nightmares (206 reports). 
The second most commonly reported 
drug is meﬂ  oquine (Lariam), a drug 
noted for triggering psychosis, with 
132 reports. Antidepressants occupy 
six of the top ten slots for reports of 
nightmares. As mentioned above, 
clinicians report between one and ten 
percent of adverse events to regulators 
and thus the incidence of nightmares 
on paroxetine is substantial. 
    What Our Findings Add to Earlier 
Reports
    Our main ﬁ  nding is that unselected 
sets of placebo-controlled trials of 
antidepressants show evidence for an 
increased relative risk of aggressive 
behaviours on treatment, although 
such outcomes apply to only a small 
subset of patients. The relative risks 
cited here reﬂ  ect a net balance of 
treatment-induced beneﬁ  ts and 
adverse outcomes. If treatment with 
an antidepressant, such as paroxetine, 
lowers the overall risk of aggression 
in a proportion of patients in a trial 
population, then the real rate of 
treatment-induced difﬁ  culties with 
paroxetine may be somewhat higher 
than the net ﬁ  gures from placebo-
controlled trials indicate. Studies in 
healthy volunteer populations in which 
treatment would not be expected to 
reduce aggressive episodes stemming 
from an underlying clinical condition 
might help clarify this point. 
    Data from pharmacovigilance studies 
support these clinical trial ﬁ  ndings, and 
the literature on antidepressant drugs 
offers several plausible mechanisms 
through which such effects might be 
mediated. 
    One strength of the current study is 
that the data are unselected. The data 
are consistent, although they come 
from a variety of sources. A weakness 
of the study is that we have been able 
to include only a subset of existing data 
in the analysis. Data on aggression on 
other antidepressants will necessarily 
have been collected as part of the 
development programmes for these 
drugs, but these data are not in the 
public domain. The sample of patients 
cited here is therefore relatively small, 
especially when selected age-groups 
and indications are considered. The 
wide conﬁ  dence intervals reﬂ  ect these 
limitations.
    Earlier reports have linked 
antidepressants to violence [38], but 
this is the ﬁ  rst independent study to 
offer a quantitative analysis of the issue; 
no other studies exist with which our 
results can be compared. 
  Legal  Implications
    The legal system has in recent years 
been faced with a number of cases 
of violence in which antidepressant 
treatment may have played a part. If 
antidepressants can in principle trigger 
violence, a need will always remain 
to establish whether such a general 
possibility might have been realised 
in an individual case. The principles 
involved in making such assessments 
will involve a consideration of the 
timing of the events in relation to 
treatment, the merits of competing 
explanations, and the existence of 
  Table 3.   Summary of Illustrative Cases   
Name and 
Year of Trial
Location Drug and Indication Sex  Age Crime Outcome Which 
Author
DS 2001 Wyoming, US Paroxetine; anxiety/depression M  60 Homicide Civil case; SKB 80% responsible DH
NH 2002 Scotland Paroxetine; bereavement F  18 Assault Guilty, but drug contributed DH
DH 2001 NSW, Australia Sertraline; anxiety/depression M  74 Homicide Guilty, but drug contributed DH
MB 2004 WA, Australia Venlafaxine; anxiety/depression F  33 Attempted murder Suspended sentence; drug implicated DH
AT 2004 England Fluoxetine; depression F  20 Robbery and assault  Guilty; drug not implicated; 3 years jail. 
Appeal dismissed.
AH
MC 2006 England Paroxetine, zopiclone, alcohol; 
depression/anxiety
M  25 Homicide Guilty; drugs not implicated; 13 years 
jail. Appeal being prepared.
AH
JB 1996 Mississippi, US Fluoxetine, benzodiazepines; 
depression/anxiety
M  66 Homicide Not guilty by reason of insanity. 
Recovered but hospitalised. Civil action 
against Lilly and Roche settled in 2005.
DM
LD 2006 Florida, US Sertraline,  paroxetine, alprazolam; 
panic disorder
F  31 Homicide Convicted; awaiting sentence DM
CP 2005 South Carolina, US Sertraline; no diagnosis M  12 Homicide and arson Guilty; 30 years jail; under appeal DH
  DOI:  10.1371/journal.pmed.0030372.t003 
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evidence in a particular case for a 
mechanism through which treatment 
may have led to violence. 
    At present, different jurisdictions 
take differing approaches to the 
issue of whether treatment with a 
prescription drug can be invoked 
as a possible defence or mitigating 
factor in cases of murder or violence. 
The question of what legal defences 
are appropriate in such cases needs 
to be addressed, as do the possible 
implications of such defences for a 
defendant and society. 
    Broadly speaking, treatment-related 
difﬁ  culties of this sort fall under 
the heading of automatisms. An 
automatism is deﬁ  ned as a transient, 
non-recurrent mental malfunction 
caused by an external factor, whether 
physical or psychological, that the 
mind of an ordinary person would be 
unlikely to have withstood and that 
produces an incapacity to control his 
or her acts. However, the question of 
automatisms has not been mapped 
onto the domain of potential problems 
that might result from prescription 
drug use, as outlined here.
    In the DS and DH cases (see Annex), 
it seems reasonable to argue for an 
automatism. These men may have 
been overwhelmed by the effects of 
prescribed medication to the extent 
that they may not have been able at 
the time to form a clear intention 
to engage in the acts that resulted 
in the deaths of their families. The 
case of MC may have involved a case 
of sleepwalking, which provides 
a classic defence of automatism. 
The CP case may have involved 
command hallucinations. JB had a 
clear delusional belief system and was 
therefore found not guilty by reason of 
insanity.
    If these cases are relatively 
straightforward medico-legally, the 
cases of NH, MB, AT, and LD are 
more complex, and may require 
medico-legal developments. The 
notion of an automatism is typically 
invoked to cover behaviours occurring 
during events such as sleepwalking 
or epileptic seizures, where normal 
consciousness is signiﬁ  cantly 
disturbed and the disturbance is of 
acute onset and brief duration. In 
contrast, MB, NH, and LD found 
themselves involved in an extended 
disturbance, in which consciousness 
was functioning well enough to allow 
them to maintain the semblances of 
normal behaviour for several weeks. 
Aside from the element of duration, 
there is a further factor. The situation 
is more like that of someone whose 
drink has been adulterated. In such 
circumstances, some of those affected 
may guess what has happened and be 
able to compensate for the hazard, 
while others may not. In the case of 
these prescription drugs, one of the 
mechanisms by which an individual 
might compensate is to check with his 
or her physician. In the cases of NH 
and LD, perceptions of difﬁ  culties may 
have been confounded by professional 
advice that the drug could not be the 
source of the problem. 
    If an element of the hazard posed by 
treatment stems from a lack of warnings 
or information, one might argue a 
particular case against the background 
of current or recent warnings. Should 
these drugs in due course come 
complete with clear warnings that were 
implemented in clinical practice, one 
might potentially take a quite different 
view, closer to the view taken about 
alcohol and violence. 
    Further complexities emerge in 
considering some of the mechanisms 
listed above. For instance, in the case 
of AT, how should the possibility of 
emotional blunting be handled? In 
the case of a drug that quells normal 
fearful responses and concern 
for consequences, it is difﬁ  cult to 
know how to determine degrees of 
responsibility. 
    For this area to move forward, more 
data are needed. Pertinent clinical trial 
data have been generated but remain 
unavailable. Combining datasets might 
make it possible to establish whether 
the risks of treatment are related to 
age and gender, or whether those 
with and without prior histories of 
aggression are affected similarly. While 
it may be that further data would show 
that the risk associated with certain 
SSRIs and tricyclic antidepressants 
may be less than others, or may not 
exist in all antidepressants, there is 
no way to make that determination 
without access to these data. Indeed, 
the issue of violence triggered by 
older antidepressants has been raised 
before [38]. Current warnings in the 
US and Canada are consistent across 
antidepressants, but in other countries, 
for instance in the UK (see Summaries 
of Product Characteristics on the 
Electronic Medicines Compendium 
Web site, http://emc.medicines.org.
uk), the wording differs from drug to 
drug. Given the new medico-legal issues 
some of these cases pose, it may well 
fall to the courts to demand that data 
now unavailable be made public. 
  Conclusion
    The new issues highlighted by these 
cases need urgent examination 
jointly by jurists and psychiatrists in 
all countries where antidepressants 
are widely used. The problem is 
international, and it would make sense 
to organise an international effort now.
    In practice, clinicians need to 
be aware of the issues, but serious 
violence on antidepressants is likely 
to be very rare. When violence is a 
suspected outcome, every case has to be 
considered carefully, on the principle 
that individuals are responsible for 
their conduct, unless there is clear 
evidence of compromised function that 
cannot be otherwise explained.  
  Annex:  The  Illustrative 
Medico-Legal Cases
  Case  1 
    DS was a 60-year-old man with a 
history of ﬁ  ve prior anxiety/depressive 
episodes. These did not involve 
suicidality, aggressive behaviour, or 
other serious disturbance. All prior 
episodes had resolved within several 
weeks. In 1990 DS had had an episode 
of depression, which his doctor treated 
with ﬂ  uoxetine. He had a clear adverse 
reaction to ﬂ  uoxetine involving 
agitation, restlessness and possible 
hallucinations, which worsened over a 
three-week period despite treatment 
with trazodone and propranolol that 
might have been expected to minimise 
the severity of such a reaction. After 
ﬂ  uoxetine was discontinued DS 
responded rapidly to imipramine. 
    In 1998, a new family doctor, 
unaware of this adverse reaction to 
ﬂ  uoxetine, prescribed paroxetine 20 
mg to DS, for what was diagnosed as 
an anxiety disorder. Two days later 
having had, it is believed, two doses of 
medication, DS using a gun put three 
bullets each through the heads of his 
wife, his daughter who was visiting, and 
his nine-month-old granddaughter 
before killing himself.
    At jury trial in Wyoming in June 
2001, instigated by DS’ surviving son-
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in-law, a jury found that paroxetine 
“can cause some people to become 
homicidal and/or suicidal” [39]. 
SmithKline Beecham was deemed 80 
percent responsible for the ensuing 
events [1]. The documentary evidence 
included an unpublished company 
study of incidents of serious aggression 
in 80 patients, 25 of which involved 
homicide. 
    Experts for the plaintiff suggested 
that the mechanism through which 
paroxetine contributed to these events 
was probably akathisia or psychosis. A 
central problem with both akathisia 
and psychosis in such contexts is that 
the takers of medications often fail 
to recognise the fact that the state 
they are in is drug-induced and that 
discontinuing treatment can alleviate 
the symptoms.  
  Case  2
    NH was 18 when prescribed 
paroxetine 20 mg/day by her 
general practitioner (GP) in 
Scotland following the death of her 
grandmother, at the end of November 
2001. Within days, she became 
markedly somnolent, agitated, and 
emotionally labile. There was an 
increasing series of arguments at 
home, and unprecedented aggression. 
After eight weeks, her parents, 
concerned about the situation, 
brought her back to the GP, who 
increased the dose of paroxetine to 
30 mg. One week after the increase of 
dose and two months after the initial 
prescription, NH was involved in an 
incident at a nightclub in which she 
assaulted another person. 
    The dose of paroxetine was reduced 
to 20 mg. Her behaviour remained 
unstable, disinhibited, and there was 
at least one suicidal act. Three months 
later she stopped treatment. She had 
signiﬁ  cant withdrawal problems, but 
her behaviour normalised. Having 
been out of work for close to a year she 
went back to work and has remained in 
employment since.
    NH pled not guilty by virtue of an 
automatism. The case was heard in 
open court where the jury found her 
guilty but added “that antidepressants 
had contributed to her actions on the 
day in question”. The judge imposed a 
suspended sentence, stating that “but 
for Seroxat you wouldn’t be standing 
here”. This case appears to have 
involved treatment-induced akathisia.
  Case  3
    DH was a 74-year-old man from New 
South Wales with a history of mixed 
anxiety/depressive episodes, many of 
which resolved without drug treatment. 
He had no history of violence or 
suicidality, and had remained gainfully 
employed throughout.
    During one of these episodes, DH 
was given sertraline (Zoloft) by a GP 
and clearly responded adversely to 
this, most notably with agitation. He 
stopped treatment the following day on 
medical advice. In July 1999, he sought 
help from his GP, who was on leave. 
DH was seen by a locum who admitted 
in Court that he had not checked DH’s 
ﬁ  le before prescribing sertraline 50 mg. 
That night, apparently feeling worse 
after a ﬁ  rst dose of sertraline, DH took 
four more doses of sertraline.
    The next morning, after his wife 
got up he met her in the kitchen and 
strangled her. He then set off in his 
car, having decided to kill himself, 
but turned round and contacted the 
police to tell them what had happened. 
He decided he should accept the 
consequences of his actions and did 
not want to distress his family further.
    DH’s lawyers had intended to defend 
the case on the basis of non-insane 
automatism or involuntary intoxication, 
but before the proceedings in May 
2001, the Crown made an offer that if 
DH pleaded guilty to manslaughter on 
the basis of substantial impairment, the 
Crown Prosecutor would not contest 
any defence submission that DH be 
released from gaol on the date of his 
sentence. Further, the Crown accepted 
the case put forward by the defence 
implicating sertraline. DH accepted 
that offer in view of his age (78). The 
judge in his summing-up released DH 
and stated: “I am satisﬁ  ed that but for 
the Zoloft he had taken he would not 
have strangled his wife” [40]. 
    This case might best be explained in 
terms of a treatment-induced akathisia 
or delirious state.
  Case  4
    MB was a 33-year-old woman with two 
children who had untreated nervous 
problems since her teenage years. 
In 2001 she approached her GP who 
prescribed paroxetine. An initial 20 
mg dose was increased to 30 mg. MB 
appeared to become more anxious 
and agitated. This deterioration led 
to a switch to venlafaxine, which was 
successively increased to 300 mg/day. 
During these increases, the medical 
notes record her as being more anxious 
and agitated, but did not link this to 
treatment. 
    She made plans to take her own 
and her children’s lives, and taking 
the children for a drive, attached a 
hosepipe to the exhaust. In the course 
of two efforts to execute this plan, she 
thought better of it and informed both 
the police and child-care authorities 
what had happened. Her children were 
taken into care and she was charged 
with attempted murder. 
    During the sentencing in the 
Supreme Court of Western Australia in 
April 2004, the judge stated there were 
substantial grounds for implicating 
venlafaxine in MB’s behaviour, and 
gave her a suspended sentence [41]. 
This case again appears to involve 
treatment-induced akathisia.
  Case  5
    AT had a baby daughter in December 
2000 at the age of 17. In June 2003, 
her GP noted that she had been 
“low for 2 years, worse recently”, and 
prescribed ﬂ  uoxetine 20 mg. Before 
treatment she was noted to be “self-
harming with superﬁ  cial abrasions 
to her lower limbs underneath her 
trousers and has been thinking of 
hanging herself. She has not planned 
to as she would not do that to her 
daughter and has no immediate plans 
of suicide of any description.”
    Three weeks later she robbed a 14-
year-old boy of his phone and watch. 
Two days later she stole another phone. 
Four days later, a psychiatrist noted: 
“She tells me that the intensity and 
the distress caused by [the suicidal] 
thoughts have subsided since starting 
treatment with ﬂ  uoxetine. [She] feels 
that her mood did initially improve 
on ﬂ  uoxetine but that this effect is 
now wearing off.” He concluded “it 
seems that she has partially responded 
to treatment with ﬂ  uoxetine…I have 
advised her to increase the dose of 
ﬂ  uoxetine to 30mg in the morning.” 
She did as advised but the day after, 
as well as ﬁ  ve days later, she engaged 
in further robberies. Three weeks 
later she attempted robbery with an 
offensive weapon.
    In October, a forensic psychiatrist 
examining her in prison noted that 
for the preceding two months, while 
in prison she had been prescribed 
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mirtazapine 30 mg nightly (a non-
SSRI), and had become calmer and 
better able to discuss her situation. 
The writer “would now be surprised if 
she reverted to her [previous criminal] 
behaviour.”  
    AT had never before been involved 
in criminal behaviour. Her ﬁ  rst two 
offences took place 17 and 19 days after 
she started ﬂ  uoxetine. They appear to 
have been impulsive and were marked 
by complete lack of feeling. The third, 
fourth, and ﬁ  fth offences occurred 
after a dose increase. The ﬁ  fth offence 
involved brutal violence and use of a 
ﬂ  ick knife. The prison assessment took 
place when she had been off the drug 
for about ten weeks, long enough to 
eliminate the drug. 
    Her ﬁ  nal charges involved robbery 
and assault as well as child neglect. 
Based on the medical records, one 
of us (AH) noted in his report to 
the court that AT appeared to have 
suffered treatment-induced emotional 
blunting. However, the judge in this 
English case doubted that the effects of 
the drug could explain the deliberate 
planning of robberies and she was 
found guilty and sentenced to three 
years in prison with no allowance for 
any contribution from ﬂ  uoxetine. An 
appeal was rejected. 
  Case  6
    MC started drinking alcohol socially 
in 1995 at the age of 17. He used 
ecstasy in 1999 but stopped after a bad 
experience. He began using cocaine 
from February 2001, increasing 
during October through to June 2002, 
ultimately using 6 g/day for a short 
time. After July 2002 MC’s cocaine use 
reduced to nil, apart from four minor 
relapses. He had none after May 2003. 
MC’s alcohol use increased to four to 
ﬁ  ve cans of lager a night in 2002. 
    He was prescribed paroxetine 20 
mg/day for depression in late May 
2002. During the ﬁ  rst two months on 
paroxetine he experienced “terrible 
shaking of the hands; couldn’t pick 
up a glass of milk without spilling it”, 
felt nausea and had “a constant dull 
headache, as if squinting in sunlight”. 
When he missed a tablet of paroxetine, 
he wanted to hide under a duvet 
and to stay away from everybody; his 
hands shook, and he had headaches 
and nausea. These symptoms lasted a 
couple of days, and he learned not to 
miss a dose.
    In September, his GP increased 
paroxetine to 30 mg “because he was 
still very anxious”, and advised him 
to take the paroxetine earlier, when 
its stimulant effects would be more 
acceptable, rather than late. He was 
also started on a regular zopiclone 
prescription at this point to counter 
paroxetine stimulation. Soon after, 
another doctor in the practice changed 
him to the more sedating dothiepin, 
but after a few weeks he asked to be put 
back on paroxetine. He subsequently 
stopped cocaine but began drinking 
more heavily. Prescriptions of 
paroxetine and zopiclone continued 
through to July 2003.
    At this stage he was estranged from 
an ex-partner with whom he had a 
now 18-month-old daughter. In August 
2003, at her home, after ten pints of 
lager, he took two zopiclone tablets. 
Following an argument, they had a pint 
of beer each, during which there was 
another bout of quarrelling, and she 
went to bed alone, leaving him to sleep 
on the sofa. MC may have taken four 
more zopiclone tablets. He appeared 
later that night blood-stained in the 
local police station with his daughter in 
his arms. The police found his partner 
dead from multiple stab wounds. He 
was charged with murder.
    In prison paroxetine 30 mg was 
continued; zopiclone was stopped. 
During his initial period on paroxetine, 
and then in prison, MC complained of 
“terrible nightmares, waking dripping 
with sweat, soaking the bed”. Intense 
frightening nightmares have been 
reported regularly in healthy volunteers 
taking paroxetine. MC had no reported 
episodes of sleepwalking before using 
paroxetine, but he had a number of 
documented episodes of sleepwalking 
after starting the drug, and two ﬁ  rst-
degree relatives had a history of 
sleepwalking. Sleepwalking has been 
reported in association with zolpidem, 
a hypnotic related to zopiclone 
[42–44], but no case of sleepwalking 
on zopiclone has been reported in the 
scientiﬁ  c literature. However, as noted 
above, zopiclone is the drug most 
commonly linked to sleepwalking in 
Yellow Card reports to the MHRA.
    Clearly violence follows domestic 
arguments, and is a known effect of 
alcohol, but this case offers grounds 
also to implicate paroxetine and 
zopiclone. Zopiclone is known to 
cause a dose-dependent confusion and 
amnesia comparable to that found with 
benzodiazepines [45]. Violence cannot 
however be attributed to a direct effect 
of paroxetine alone, since MC had 
been maintained on this for almost 
one year with no prior violence. In 
these circumstances MC pleaded guilty 
at his trial on 27 February 2006. The 
judge did not accept that paroxetine 
and zopiclone had played any part, and 
sentenced him to 13 years prison. An 
appeal against the sentence is being 
prepared.
  Case  7
    JB was 66 years old, married to a 
second wife ten years his junior. They 
had marital difﬁ  culties, with frequent 
arguments but no history of violence. 
JB had medical complaints and 
longstanding depression and anxiety. 
Digestive symptoms were treated with 
an antispasmodic combined with 
chlordiazepoxide (5 mg four times 
daily); generalised anxiety was also 
treated with chlordiazepoxide (10 mg 
twice daily); an undiagnosed movement 
disorder, characterized by twitches 
and tics, was treated with clonazepam 
(0.5 mg at night). In addition, JB had 
been treated with the antidepressant 
doxepin 75 mg at night for years. 
    Concerned about the sedative effects 
of his medication, JB’s wife began 
replacing active doxepin powder with 
sugar in an attempt to offset this effect. 
JB suspected the capsules had been 
tampered with. His wife admitted 
doing this when they saw a new 
psychiatrist in mid-August 1994. The 
doctor considered JB to have major 
depression with anxiety, complicated 
by physical symptoms and marital strife. 
He noted that JB was not psychotic 
or suicidal, and agreed that doxepin 
be discontinued, instead prescribing 
ﬂ  uoxetine 10 mg daily, continuing the 
other medications as before.
    JB was meticulous about compliance 
and even kept a medicines log. He 
remained concerned that his wife was 
tampering with his pills, and after four 
weeks ﬂ  uoxetine accused her of being 
unfaithful. Alarmed at his suspicions, 
his wife rang the psychiatrist and 
disposed of the household gun. 
Meanwhile, JB’s friends noted that, 
normally placid, he had become tense, 
strange, and suspicious; he asked 
for a replacement gun to defend 
himself; described a plan to escape an 
expected attempt on his life; feared 
September 2006  |  Volume 3  |  Issue 9  |  e372PLoS Medicine  |  www.plosmedicine.org 1485
poisoning of food and drink; feared 
an ambush when visiting his mother’s 
grave. Two months after starting 
ﬂ  uoxetine JB had become ﬂ  oridly 
deluded, expecting to be attacked or 
poisoned by his wife, or her agent. 
The psychiatrist received phone calls 
of concern from friends and family 
but did not alter his treatment. One 
evening in mid October 1994 JB 
approached his neighbours, covered 
in blood, reporting an attack by his 
wife. He had several minor cuts to his 
arms. His wife was found dead in their 
hallway, in a pool of blood with 200 
stab wounds. 
    In 1996, a Mississippi court found 
JB not guilty of murder by reason of 
insanity [46]. He was conﬁ  ned to a 
mental hospital, where he remains, 
even though on review of his medical 
notes by one of us (DM), it was clear 
that his psychosis cleared on withdrawal 
of ﬂ  uoxetine, and further treatment. 
His physicians are concerned about 
the risk should he be discharged. 
Although prescription drugs were not 
invoked in his defence, a subsequent 
civil case seeking damages from Eli 
Lilly (Prozac) and Hoffman LaRoche 
(benzodiazepines) was settled in 
2005 (personal communication from 
plaintiff’s lawyer, R. Boyd). This 
homicide case involves a treatment-
induced psychosis.
  Case  8
    LD, a 31-year-old mother, separated 
from the father of her 3-year-old twin 
boys in 2001. After a protracted custody 
battle, she began experiencing episodes 
of dizziness, sweating, shaking, nausea, 
and pressure in the chest. She was well 
between episodes, experienced no 
suicidality, irritability, or aggression, 
and continued to care for her sons as 
before, living in the same house as her 
father and his second wife.
    Reading a magazine, she saw an 
advertisement for “panic disorder”, 
and recognised many of the symptoms 
described in it. She contacted her 
family doctor, but no appointments 
were available and she saw the nurse 
practitioner instead. She was given a 
free starter pack of sertraline 25 mg, 
and a prescription for alprazolam 0.5 
mg twice daily to start immediately. 
    LD found the drugs stopped her 
panic attacks, but she experienced 
increasing tension, restlessness, and 
agitation, which worsened when 
the “starter pack” dose of sertraline 
increased after one week from 25 to 50 
mg/day. Other unexpected effects were 
that her previous moderate alcohol 
intake took on a compulsive quality, 
and she became increasingly depressed 
and began to think of suicide. On 
one occasion she found herself in the 
closet holding her father’s pistol before 
“coming to” and realising what she 
was doing. Alarmed, she tried to see 
her doctor, but he was not available. 
She again saw the nurse, who switched 
her from sertraline, which she had 
taken for a month, to a starter pack 
of paroxetine 20 mg/day and advised 
continuing alprazolam at 1 mg/day. 
    LD’s agitation, restlessness, 
depression, and suicidal ideas 
worsened. Two days after the switch 
to paroxetine, she claims she took 
double the prescribed amount of both 
paroxetine and alprazolam, hoping 
this would help. It didn’t. She drank 
alcohol and sounded intoxicated on 
the phone. Claiming she saw no future 
for herself or her children, she shot 
both in the head just before their 
afternoon nap. She recalls intending to 
kill herself as well, but did not do this 
immediately as she noticed one son 
was still breathing. Unwilling to “leave 
him behind”, she waited but passed 
out from her overdose of alprazolam 
and alcohol, and was discovered deeply 
asleep with her twins dead next to her. 
Her blood and urine alcohol levels 
showed marked intoxication.
    The Florida State Attorneys 
initially sought to have LD convicted 
of murder and sentenced to death, 
but later dropped pursuit of the 
death penalty. The defence team 
contended that LD was not guilty by 
reason of temporary insanity caused 
by the prescription drugs provided 
by the nurse practitioner. Prior to 
trial a “Frye” hearing was held to 
consider whether evidence regarding 
SSRI-induced akathisia, involuntary 
alcohol intoxication, suicidality, and 
homicidality would be admissible. 
The judge ruled that evidence could 
be admitted indicating that akathisia 
was   associated   with SSRI treatment, but 
that a   causal   relationship could not 
be argued. With this restriction on 
defence testimony, the State Attorneys 
convinced the jury that the drugs did 
not play a causal role in the homicides. 
LD was convicted, and sentenced to life 
without possibility of release [47]. 
  Case  9
    According to an independent forensic 
report compiled a year after the 
events for which CP was charged in 
November 2001, CP was a 12-year-
old, 5’2”, 95-lb boy with a family 
background involving considerable 
social dislocation. Despite the 
difﬁ  culties of his social situation, 
he had no record of treatment for 
nervous disorders or of violence or 
behavioural disturbance. Following 
an argument with his father at the 
end of October 2001, he was admitted 
to a behavioural centre for six days 
where he was started on paroxetine. 
His behaviour worsened daily on 
paroxetine. He was discharged 
against medical advice to the care 
of his grandparents, who, when his 
paroxetine ran out, took him to their 
primary-care physician who prescribed 
sertraline 50 mg, increasing this to 
100 mg two days before the killings for 
which CP was charged. The duration 
of sertraline treatment was three 
weeks.
    After the prescription of sertraline, 
CP was involved in a number of 
aggressive incidents at school, the ﬁ  rst 
on record for him, and was reported by 
family members and church members 
to be restless and talking unusually 
volubly. Relatives noted a series of risky 
behaviours. On the day of the killings, 
his grandparents had told him that he 
could not take the school bus following 
an episode of aggression toward one 
of the other children on the bus. Later 
that evening he attended choir practice 
with his grandparents, who in response 
to escalating difﬁ  culties had warned 
him he might have to be returned to 
his father.
    The independent forensic report on 
the case notes CP as saying that that 
night: “something told me to shoot 
them”. He had initially reported this 
to be hallucinations and then said he 
thought it was his own thoughts. When 
asked to speciﬁ  cally describe what 
the experience was like, he said it was 
“like echoes in my head saying ‘kill, 
kill’, like someone shouting in a cave”. 
According to the forensic report, “He 
reported this began happening after he 
went to bed...He reported he had never 
considered harming his grandparents 
before and this was unlike anything 
he had previously experienced. He 
reported that the voices were coming 
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from inside his head and they bothered 
him so much that he got up. He 
reported that the voices continued 
until he killed his grandparents. He 
reported that he couldn’t control 
himself and reported the echoes 
stopped after he shot his grandparents. 
He set ﬁ  re to the house but could 
not explain these actions saying the 
thoughts just popped up”. He then 
took a vehicle and began driving but 
reported that he had no idea where 
he was going and that it all felt like a 
dream. He recalled asking the police 
about his grandparents after he was 
picked up because he was not sure if it 
had really happened or not.    
    These events and CP’s overall 
behaviour and history led an 
independent forensic child psychiatrist 
to diagnose substance-induced mania 
and psychotic disorder. The charges of 
double murder and arson were heard 
by jury trial in an adult rather than 
juvenile court. In the process of jury 
selection, 32 of 75 prospective jurors 
declared that they or someone related 
to them were on or had been on an 
antidepressant. Court TV covered the 
trial in its entirety. Both prosecution 
and defence from the outset accepted 
that CP had shot his grandparents. 
Media coverage focused heavily on 
the question of “‘Evil’ or ‘chemically 
compelled’?” 
    In February 2005, after a two-week 
trial, a jury found CP guilty of murder 
and he was sentenced to 30 years in 
prison [48]. Questioned by the media 
afterwards, “Steven Platt, a 26-year-
old accounting clerk for an electrical 
supply wholesaler, said the group 
believed that Christopher exhibited 
side effects from Zoloft but did not 
feel it was severe enough to let him 
escape criminal responsibility” [49]. 
Summing up some of the points at 
issue, the judge Daniel Pieper stated: 
“There is no case in South Carolina 
that addresses involuntary intoxication 
by prescription drugs…It seems to turn 
the whole medical system on its side if 
you can’t rely on the medication your 
doctor prescribes. It could potentially 
force you into a situation of lifetime 
commitment if that drug induces an 
effect of which you’re not aware…
There’s something disconcerting about 
that, albeit probably something of a 
legal nature that is troubling me” [50]. 
The verdict is currently under appeal in 
the South Carolina Supreme Court. 
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